rare cancers europe sqA course for Patient Advocates

Milan, Italy, 20 July 2015

Rare cancers Europe (RCE) is offering a course for patient advocates in the Methodology of Clinical Studies in rare cancers.

Registration is free.  To inquire about registration, please contact Francesa Longo at Rare Cancers Europe RCE: francesca.longo@esmo.org

Currently RCE can offer 40 travel grants up to max. 500 EUR each to be allocated after the event and upon submission of travel and accommodation receipts. Travel Grant applications will be considered on a first come first served basis. Travel grants will be allocated on a geographical and patient group base, accepting no more than 2 requests per association and country. Additional requests will be kept in a waiting list and processed at a later stage, based on the amount of financial support still available.

More than 4.3 million people in the European Union are affected by rare cancers. Despite the rarity of each of the 198 rare cancers, they represent in total about 22% of all cancer cases, including all cancers in children, diagnosed in the EU28 each year.  Kidney cancer is one of the less prevalent cancers, and the genetic syndromes that may cause kidney cancer are each quite rare.
Rare Cancers Europe (RCE) is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the  European policy agenda and to implementing 39 political and stakeholder recommendations. From the very early beginning – IKCC is a member of Rare Cancers Europe, and Patient Advocates are on the Steering Committee of RCE – together with ESMO, EORTC, ESO and Novartis.

More complete information about rare cancers and the initiative can be found on the RCE website, notably: